Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

NCT00097955 Phase 2 COMPLETED

Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	COMPLETED
Enrolment	496
Start date	2004-10
Completion	2007-04

Conditions

• Diabetic Nephropathy

Interventions

• aliskiren

Primary outcomes

• Change from baseline in urinary albumin creatinine ratio after 24 weeks

Countries

United States, Canada, Denmark, France, Germany, Greece, Italy, Netherlands, Romania, Russia, Spain, United Kingdom